Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

NCT03101423 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Beta Thalassemia Major

Interventions

DRUG: Interleukin-2
DRUG: Donor Regulatory T-Lymphocytes

Sponsor

First Affiliated Hospital of Guangxi Medical University